A Quote by Ben Goldacre

In general, drug companies are reasonably good at developing new treatments, and there's also a lot of good in the industry. — © Ben Goldacre
In general, drug companies are reasonably good at developing new treatments, and there's also a lot of good in the industry.
While many have been left behind by Part D, there is a clear winner: the drug industry. Independent analysts predict that Part D will increase drug industry profits by $139 billion over the next eight years. Glaxo-SmithKline's second-quarter net income already jumped 14 percent, and other leading drug companies also have benefited.
We've got to get our drug industry back. Our drug industry has been disastrous. They're leaving left and right. They supply our drugs, but they don't make them here, to a large extent. And the other thing we have to do is create new bidding procedures for the drug industry because they're getting away with murder.
I hope there will be some good news and some good profits, and people will realize we have a lot of outstanding executives, and a lot of companies that are doing a good job, and those are good companies to invest in.
I see a lot of tech companies developing technology here and selling it abroad, but I don't see new factories being built, and that worries me, because it means we are not creating the jobs that will guarantee a good life for Israelis.
If there was any drug that was to symbolize the people that ate our heroes, it seems like bath salts was a good idea. It's also a drug that, I think, is still funny to a lot of people.
As James Surowiecki noted in a New Yorker article, given a choice between developing antibiotics that people will take every day for two weeks and antidepressants that people will take every day for ever, drug companies not surprisingly opt for the latter. Although a few antibiotics have been toughened up a bit, the pharmaceutical industry hasn't given us an entirely new antibiotic since the 1970s.
Drug companies spend more on advertising and marketing than on research, more on research on lifestyle drugs than on life saving drugs, and almost nothing on diseases that affect developing countries only. This is not surprising. Poor people cannot afford drugs, and drug companies make investments that yield the highest returns.
The moment the doctor said he wanted to do a biopsy, in my heart I thought I'd probably got it. But I also know a lot of people who have also had prostate cancer, so I had a reasonably good idea what to expect.
Autism is a complicated illness, and children with a variety of treatments and non-treatments show improvement over time, which is all to the good.
There are companies that are good at improving what they're already doing. There are companies that are good at extending what they're doing. And finally there are companies that are good at innovation. Every large company has to be able to do all three - improve, extend, and innovate - simultaneously.
Drug companies should not be allowed to reap excessive profits or spend unreasonable amounts on marketing if they want to receive support that is designed to encourage life- saving and health-improving treatments.
Balance in general is difficult, but I refuse to go through life and just have work and not have good balance. I want to be an example, not only to my own children but also to artists and other entrepreneurs, that you can be a workaholic and also be a good husband and good father.
We've run out of good projects. This is not a money issue... If these oil companies had fantastic projects, they'd be out there [developing new fields].
Our society is very, very good at developing certain types of skills and certain types of genius. We are fantastically good at identifying and developing athletic skills - better than we are, really, at almost anything else. We are quite good at developing and rewarding inventiveness.
We've grown from 18% of the profits of the top 25 companies in our industry to 23% of the profits of the top 25 companies in our industry over the last five years. Profits are up over 70%, where the industry profit is up about 35%. Pretty good.
In case you haven't noticed, a large wall is being built around the American people to ensure that they remain prisoner to the drug industry. It's easy to understand why drug makers want to force Americans to buy their products in the United States. Ours is the only industrialized country that doesn't negotiate the prices the drug companies may charge. As a result, a 90-day supply of Fosamax sells for $105 in Canada but $210 here.
This site uses cookies to ensure you get the best experience. More info...
Got it!